Metformin: Beyond Diabetes—Exploring Its Impact on Weight, Heart Health, and Lifespan
Metformin, a medication commonly prescribed for type 2 diabetes, has garnered attention for its potential benefits extending beyond blood sugar control. Recent research suggests that metformin may aid in weight loss, enhance cardiovascular health, and even contribute to increased longevity.
Studies indicate that metformin can promote modest weight reduction in individuals with and without diabetes. This effect is particularly significant for those struggling with obesity, as weight loss is closely linked to improved heart health. By reducing body weight, metformin may help lower the risk of heart disease, which remains a leading cause of mortality worldwide.
Beyond weight management, metformin exhibits properties that directly benefit the cardiovascular system. It has been shown to improve endothelial function—the performance of the inner lining of blood vessels—thereby enhancing blood flow and reducing blood pressure. Additionally, metformin's anti-inflammatory and antioxidant effects may protect against the development of atherosclerosis, a condition characterized by the hardening and narrowing of arteries. These combined effects not only support heart health but also suggest a role for metformin in promoting a longer, healthier life.
Article Information
The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity
Published in Cardiology in Review. Pillai et al.
Abstract
Metformin, a biguanide derived from Galega officinalis, was first synthesized by Werner and Bell in 1922. Metformin was approved for the treatment of diabetes by the US Food and Drug Administration in 1994. It has since become the most widely used oral antidiabetic agent. The exact mechanisms by which metformin exerts its clinical effects remain the subject of ongoing research. Metformin interacts with multiple molecular pathways, and the downstream effects of which affect weight, cardiovascular health, and longevity. Metformin reduces hunger by mitigating insulin resistance in the hypothalamic pro-opiomelanocortin neurons. It enhances satiety by stimulating the enteral release of glucagon-like peptide 1. It also induces favorable changes to enteric microbiota, enhancing metabolism. These effects cumulatively contribute to metformin-induced weight loss. Metformin use has shown associations with improved cardiovascular outcomes including reduced all-cause mortality, lower rates of myocardial infarctions, and improved heart failure outcomes. Many of these actions are mediated through the direct activation of adenosine monophosphate-activated kinase (AMPK), which, in turn, enhances cellular energy production and endothelial nitric oxide synthase-mediated vascular relaxation. It antagonizes proinflammatory cytokines, reducing cardiac fibrosis and remodeling. The metformin-AMPK pathway may also explain the potential utility of metformin in mitigating aging. Acting through AMPK, it inhibits the mammalian target of rapamycin, leading to increased autophagy and cell growth. The metformin-AMPK-sirtuin pathway may also contribute to longevity. In this review, we will discuss the use of metformin in weight loss, cardiovascular health, and longevity, highlighting the historic background, molecular mechanisms, and current evidence.
Bring preventive care to your clinic
© Longevity Artificial Intelligence. All rights reserved.